Difference between revisions of "MEDICATION-ADRENALINE"

From NeuroRehab.wiki

(Imported from text file)
(Imported from text file)
Line 1: Line 1:
[[Summary Article|<h5>'''SUMMARY ARTICLE'''</h5>]]
[[Summary Article|<h5>'''SUMMARY ARTICLE'''</h5>]]
<br/>
<br/>
<div>1. Naturally occurring catecholamine with <i>alpha </i>(vasoconstriction) & <i>beta </i>effects.<div>2. Administer in the setting of cardiac arrest to cause vasoconstriction and to redirect available CO to the myocardium & brain.</div><div>3. It raises diastolic pressure thereby improving coronoary perfusion and facilitating defibrillation by improving myocardial blood flow during CPR.</div><div>4. Indications: asystole, PEA, pulseless VT/VF, bradycardia unresponsive to atropine.</div><div>5. Given IM in the setting of anaphylaxis: 0.5 mg every 15 min.</div><div>6. SE: tachycardia, HTN, arrhythmias, tissue necrosis if extravasation occurs, hyperglycaemia.</div><div><br></div><div>DOSAGE</div><div>7. Administer 1 mg every second loop of CPR (1:10,000 via IV cannula or 1:1000 via central line).</div><div>8. Infusion of 1-20 mcg/min in ICU.</div>
<div>1. Naturally occurring catecholamine with <i>alpha </i>(vasoconstriction) &amp; <i>beta </i>effects.<div>2. Administer in the setting of cardiac arrest to cause vasoconstriction and to redirect available CO to the myocardium &amp; brain.</div><div>3. It raises diastolic pressure thereby improving coronoary perfusion and facilitating defibrillation by improving myocardial blood flow during CPR.</div><div>4. Indications: asystole, PEA, pulseless VT/VF, bradycardia unresponsive to atropine.</div><div>5. Given IM in the setting of anaphylaxis: 0.5 mg every 15 min.</div><div>6. SE: tachycardia, HTN, arrhythmias, tissue necrosis if extravasation occurs, hyperglycaemia.</div><div><br/></div><div>DOSAGE</div><div>7. Administer 1 mg every second loop of CPR (1:10,000 via IV cannula or 1:1000 via central line).</div><div>8. Infusion of 1-20 mcg/min in ICU.</div>


==Reference(s)==
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council.
<br/>American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons.


[[Category:Medication]]
[[Category:Medication]]
[[Category:Advanced Life Support]]
[[Category:Advanced Life Support]]

Revision as of 12:30, 21 December 2022

SUMMARY ARTICLE


1. Naturally occurring catecholamine with alpha (vasoconstriction) & beta effects.
2. Administer in the setting of cardiac arrest to cause vasoconstriction and to redirect available CO to the myocardium & brain.
3. It raises diastolic pressure thereby improving coronoary perfusion and facilitating defibrillation by improving myocardial blood flow during CPR.
4. Indications: asystole, PEA, pulseless VT/VF, bradycardia unresponsive to atropine.
5. Given IM in the setting of anaphylaxis: 0.5 mg every 15 min.
6. SE: tachycardia, HTN, arrhythmias, tissue necrosis if extravasation occurs, hyperglycaemia.

DOSAGE
7. Administer 1 mg every second loop of CPR (1:10,000 via IV cannula or 1:1000 via central line).
8. Infusion of 1-20 mcg/min in ICU.